Moderna released early clinical data showing responses in melanoma patients treated with its cancer antigen therapy (mRNA-4359) in combination with a PD-1 inhibitor, and separately posted Phase 1/2 results that underpinned a strategic expansion of its oncology portfolio. The company said the dataset persuaded it to prioritize the program and pursue further development. Moderna’s disclosures—shared ahead of ESMO and via internal data releases—underscore the biotech’s effort to extend mRNA platforms into oncology and to use early clinical signals to reallocate development resources.